News
Edison Pharma Hires Director of Medicinal Chemistry (March 20, 2006)
William D. Shrader, PhD, will lead pre-clinical and medicinal chemistry initiatives
San Jose, California, March 20, 2006 – Edison Pharmaceuticals, Inc., announced today the hiring of its Director of Medicinal Chemistry, William D. Shrader, PhD. Dr. Shrader joins Edison to assist in advancing EPI-A0001 into development for the treatment of orphan mitochondrial diseases and to manage its pre-clinical development pipeline.
“With Bill joining Edison, we have our senior technical team in place to drive our development and preclinical programs,” stated Guy Miller, CEO of Edison Pharmaceuticals. “His skills and translational capabilities will be highly enabling to both our clinical efforts and medicinal chemistry program.”
Dr. Shrader joins Edison with extensive experience in medicinal chemistry, having directed programs in thrombosis, oncology and inflammation. He has previously held positions at Abbott Laboratories and Celera Genomics, and was a National Institute of Health postdoctoral fellow at the California Institute of Technology. Dr. Shrader has been involved with programs from discovery through clinical development.
Edison is readying its first drug candidate, EPI-A0001, for clinical evaluation in Q4, 2006.
About Edison Pharmaceuticals
Edison Pharmaceuticals, Inc. is focused on the development of drugs to treat energy impairment diseases, also referred to as mitochondrial diseases. The company is advancing into clinical development EPI-A0001 for the treatment of inherited mitochondrial diseases predominately a ecting children. Edison’s technology platform consists of a specialized knowledge in redox medicinal chemistry which the company believes is essential to drugging key targets contained within mitochondria. Edison will leverage clinical and laboratory data obtained in rare, or orphan, diseases to pursue other conditions that share common mechanisms. The company has obtained substantial non-dilutive peer-reviewed grant support to advance both its pre-clinical and clinical initiatives from foundations including the Muscular Dystrophy Association, Friedreich’s Ataxia Research Alliance, and Seek A Miracle.
Contact:
Ms. Lorraine Gilmore
Manager Administration
(408) 960-2910
lgilmore@edisonpharma.com
www.edisonpharma.com